Study wrapper · #884
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
Khatami S, Faghihi M, Tavakoli G, et al. Cardiovascular toxicology. 2026.
DOI: 10.1007/s12012-026-10119-6PubMed: 42455418
Editor's note
This review pools thirteen small rodent studies and reports incretin therapies were associated with better left ventricular function during doxorubicin exposure. Semaglutide and tirzepatide each appear in only a handful of animal studies, and the authors rate certainty as low-to-very-low. Findings are explicitly hypothesis-generating with no human data, so weight is limited.
Plain-language abstract
A systematic review of rodent studies found that incretin-based drugs, including semaglutide and tirzepatide, were associated with preserved heart function during doxorubicin chemotherapy, though no human studies existed.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026